Qpct Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Glutaminyl Cyclase (QPCT) is a 360-amino acid enzyme that catalyzes the conversion of N-terminal glutamine residues to pyroglutamate (pGlu) residues. This post-translational modification, known as pyroglutamylation, has profound implications for protein stability, aggregation propensity, and biological activity. QPCT has emerged as a significant therapeutic target in Alzheimer's disease (AD) due to its critical role in generating highly neurotoxic pyroglutamate-modified amyloid-beta (pE3-Aβ) species. [1]
| Property | Value | [2]
|----------|-------| [3]
| Symbol | QPCT | [4]
| Full Name | Glutaminyl Cyclase | [5]
| Gene | QPCT | [6]
| UniProt ID | Q96KH6 | [7]
| PDB Structures | 2XUM, 3P40, 4E0L, 4E0M | [8]
| Molecular Weight | ~38.5 kDa | [9]
| Length | 360 amino acids | [10]
| Subcellular Localization | Golgi apparatus, Secreted, Cytoplasm | [11]
| Protein Family | Metallo-dependent hydrolase family |
| EC Number | 3.5.5.1 |
The QPCT protein consists of a single catalytic domain with a characteristic α/β/α sandwich fold. The active site contains a zinc ion (Zn²⁺) that is essential for catalytic activity [1]. Key structural features include:
The active site of QPCT features a zinc ion coordinated by:
This zinc-dependent mechanism allows for efficient catalysis of glutamine cyclization [1].
QPCT catalyzes the intramolecular cyclization of N-terminal glutamine residues to form pyroglutamate (pGlu) residues. The reaction proceeds through the following mechanism:
N-terminal Gln → (QPCT) → Pyroglutamate (pGlu) + NH₃
The enzyme exhibits:
QPCT participates in several important biological pathways:
QPCT plays a central role in AD pathogenesis through the generation of pE3-Aβ [2][3]:
Key Mechanisms:
In ALS, QPCT may contribute to:
QPCT activity may influence prion protein aggregation and conversion to the pathogenic prion form.
Multiple pharmaceutical companies have developed QPCT inhibitors:
| Compound | Company | Status | IC50 |
|---|---|---|---|
| PQ912 | Probiodrug | Phase 2a | 32 nM |
| PBD150 | Probiodrug | Preclinical | 0.6 nM |
| compound 5 | Merck | Preclinical | 8 nM |
| 1,2,4-triazole derivatives | Various | Discovery | nM range |
PQ912 (Wagabate):
QPCT is expressed in:
QPCT expression is regulated by:
| Biomarker | Source | Clinical Utility |
|---|---|---|
| pE3-Aβ | CSF | Disease progression |
| Total QPCT | Plasma | Treatment response |
| QPCT activity | Plasma | Target engagement |
QPCT (Glutaminyl Cyclase) is a zinc-dependent enzyme that catalyzes the formation of pyroglutamate-modified proteins. Its critical role in generating toxic pE3-Aβ species makes it a compelling therapeutic target in Alzheimer's disease. QPCT inhibitors, particularly PQ912, have advanced to clinical trials and represent a promising disease-modifying approach for AD and potentially other neurodegenerative conditions characterized by protein aggregation.
The study of Qpct Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- "Pyroglutamate-modified Aβ3-42: A novel target for immunotherapy" - Nat. Rev. Neurol. (2013). 2013. ↩︎
- "Glutaminyl cyclase activity correlates with Aβ pathology" - Acta Neuropathol. Commun. (2017). 2017. ↩︎
- "Enzymatic analysis of human glutaminyl cyclase" - FEBS J. (2009). 2009. ↩︎
- "PQ912, a glutaminyl cyclase inhibitor: First clinical results" - J. Prev. Alzheimers Dis. (2018). 2018. ↩︎
- "pE3-Aβ acts as a seed for Aβ aggregation" - J. Biol. Chem. (2010). 2010. ↩︎
- "Glutaminyl cyclase knockout mice show reduced pathology" - Neurobiol. Aging (2015). 2015. ↩︎
- "QPCT polymorphisms affect AD onset" - J. Alzheimers Dis. (2015). 2015. ↩︎
- "QPCT in ALS: A new therapeutic target?" - Acta Neuropathol. (2018). 2018. ↩︎
- "pE3-Aβ as a biomarker in Alzheimer's disease" - Alzheimers Res. Ther. (2020). 2020. ↩︎
- "The QRFP system and metabolic regulation" - Peptides (2006). 2006. ↩︎
- "The QSOX family in protein quality control" - J. Biochem. (2006). 2006. ↩︎